# CAPLIPOINT (CAPLIPOINT) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/caplipoint

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,732.1
- Change: +5.38%
- As of: 2026-09-18
- 1D return: +5.85%
- 5D return: -1.67%
- 1M return: +8.65%
- Latest complete quarter: —

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, CAPLIPOINT is trading at ₹2748.6, exhibiting a generally bullish technical stance across multiple timeframes. Daily, weekly, and monthly indicators show the price trading above key moving averages (EMA 20, EMA 50, SMA 20, SMA 50, SMA 200) and the Supertrend indicator, suggesting an uptrend is in place. The weekly and monthly timeframes also show bullish Supertrend readings. Recent patterns include an active "Morning Star" formation on the monthly chart and an active "Doji" on the weekly chart, indicating potential for continued price action. The stock's annualized volatility stands at 0.39, with a current drawdown of -0.03 and a maximum drawdown of -0.42 over its history.

Nearest support is observed around ₹2675.0 (2.68% below the current price), with further support at ₹2652.4 (3.5% below). Resistance is identified at ₹2877.3, approximately 4.68% above the current price. The stock is positioned towards the upper end of its recent trading range, with its position in the 20-period range at 0.69 and in the 252-period range at 0.91.

Key watch conditions include monitoring the price action around the nearest support levels. A sustained break below ₹2675.0 could signal a potential weakening of the immediate uptrend. Conversely, a move above the resistance level of ₹2877.3 may indicate further upward momentum.

- Current price: ₹2748.6 as of September 18, 2026.
- Bullish trend indicated across daily, weekly, and monthly timeframes, with price above key moving averages and Supertrend.
- Nearest support levels identified at ₹2675.0 (2.68% below) and ₹2652.4 (3.5% below).
- Nearest resistance level identified at ₹2877.3 (4.68% above).
- Watch for price action around ₹2675.0 support and ₹2877.3 resistance for potential trend confirmation or reversal.

- Morning Star
- Doji
- Harami
- Evening Star
- Inside Bar
- Bullish Engulfing Reversal

### News Context

Caplin Point Laboratories announced its 35th Annual General Meeting (AGM) will be held on September 25, 2026, via video conferencing. The company plans to adopt the financial year 2025-26 financials, declare a final dividend of ₹4 per share, and ratify an interim dividend, bringing the total for the year to ₹8 per share. The agenda also includes seeking approval for the re-appointment of Dr. Sridhar Ganesan as Managing Director and Mr. D. Muralidharan as Whole Time Director, along with changes to committee mandates and director roles. Additionally, the company has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, detailing its renewable energy usage, water conservation efforts, and Corporate Social Responsibility (CSR) spending of ₹4.70 Crores. The company also informed the exchange about a dividend payout of ₹4 per share with a record date of September 18, 2026.

- Caplin Point Laboratories will hold its 35th AGM on September 25, 2026, to approve FY2025-26 financials and dividends.
- The company proposed a final dividend of ₹4 per share, totaling ₹8 per share for FY2025-26.
- Key management re-appointments, including Dr. Sridhar Ganesan as Managing Director, are on the AGM agenda.
- The Business Responsibility and Sustainability Report for FY2025-26 was submitted, showing 36.65% renewable energy usage and ₹4.70 Crores spent on CSR.
- A dividend of ₹4 per share was announced with a record date of September 18, 2026.

- SERIES:EQ |PURPOSE:DIVIDEND - RS 4 PER SHARE |FACE VALUE:2 |RECORD DATE:18-Sep-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-
- Caplin Point Laboratories Limited has informed the Exchange regarding 'Letter to Shareholders'. |SUBJECT: Updates
- Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Caplin Point Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026 |SUBJECT: Shareholders meeting
- Caplin Point Laboratories Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Reporting (BRSR)'. |SUBJECT: Updates

### What Changed

Caplin Point Laboratories (CAPLIPOINT) on the NSE experienced a price increase to ₹2748.6 as of the observation date September 18, 2026, up from ₹2596.6 previously. This marks a recent upward movement in the stock's trading price. No other new developments were reported in the provided evidence pack.

- On September 18, 2026, Caplin Point Laboratories' stock price was ₹2748.6.
- The previous stock price for Caplin Point Laboratories was ₹2596.6.
- The company is listed on the NSE under the symbol CAPLIPOINT.

### Official Filings

Caplin Point Laboratories Limited has announced its 35th Annual General Meeting (AGM) scheduled for September 25, 2026, to be held via video conference. Key agenda items include the adoption of the financial year 2025-26 audited financials, which reported consolidated revenue of ₹2,171.38 Crores and a net profit after tax of ₹302.97 Crores. The company also proposes a final dividend of ₹4 per share, which, combined with a previously declared interim dividend of ₹4 per share, totals ₹8 per share for the fiscal year. The AGM will also seek shareholder approval for the re-appointment of Dr. Sridhar Ganesan as Managing Director for two years from August 25, 2026, and the appointment of Mr. D. Muralidharan as Whole Time Director for two years from August 12, 2026. Additionally, the company has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, detailing its environmental and social initiatives, including 36.65% renewable energy usage and ₹4.70 Crores spent on Corporate Social Responsibility (CSR). The company also responded to an exchange query on September 2, 2026, regarding a significant increase in trading volume, stating full compliance with disclosure regulations and attributing the surge to market-driven factors.

- The 35th AGM is scheduled for September 25, 2026, to approve FY2025-26 financials and dividends.
- Proposed final dividend of ₹4 per share, bringing the total for FY2025-26 to ₹8 per share.
- FY2025-26 consolidated revenue was ₹2,171.38 Crores and net profit was ₹302.97 Crores.
- Proposed re-appointment of Dr. Sridhar Ganesan as Managing Director and appointment of Mr. D. Muralidharan as Whole Time Director.
- Submitted FY2025-26 Business Responsibility and Sustainability Report (BRSR) on September 3, 2026.
- Responded to NSE query on September 2, 2026, regarding trading volume increase, citing market-driven factors.

- SERIES:EQ |PURPOSE:DIVIDEND - RS 4 PER SHARE |FACE VALUE:2 |RECORD DATE:18-Sep-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-
- Caplin Point Laboratories Limited has informed the Exchange regarding 'Letter to Shareholders'. |SUBJECT: Updates
- Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Caplin Point Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026 |SUBJECT: Shareholders meeting
- Caplin Point Laboratories Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Reporting (BRSR)'. |SUBJECT: Updates
- Caplin Point Laboratories Limited has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 25-Sep-2026 |SUBJECT: Notice Of Shareholders Meetings-XBRL
- Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Caplin Point Laboratories Limited has submitted their response. |SUBJECT: Spurt in Volume
- AS ON DATE : 03-SEP-26
- Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. |SUBJECT: Spurt in Volume

### Fundamentals

Caplin Point Laboratories' recent financial disclosures indicate a mixed operating performance. The company's consolidated revenue and operating profit have shown a decline in the latest reported periods. Specifically, revenue has decreased, and operating profit has followed suit, impacting the operating profit margin. Profit After Tax (PAT) has also seen a reduction, leading to a lower Earnings Per Share (EPS). The company's financial health, based on available balance sheet information, requires careful monitoring to understand its debt levels and liquidity position in the context of its operating performance.

- Consolidated revenue has declined in the latest reported period.
- Operating profit has decreased, leading to a lower operating profit margin.
- Profit After Tax (PAT) and Earnings Per Share (EPS) have also shown a reduction.
- Key monitoring areas include the company's debt and liquidity position.

### Bull Case

Caplin Point Laboratories exhibits several technical indicators suggesting a constructive market setup as of September 18, 2026. The stock's price is trading above key moving averages, including the 20-day and 50-day simple moving averages (SMA) and exponential moving averages (EMA), on both daily and monthly timeframes. The daily trend shows the 20-day SMA slope at 31.04 and the 50-day SMA slope at 7.5, indicating upward momentum. Furthermore, the daily Supertrend indicator is 'bullish' at ₹2508.16, and the weekly Supertrend is also 'bullish' at ₹2210.5, reinforcing a positive trend across multiple timeframes. The company has also demonstrated significant positive returns over various periods, including a 6-month return of 0.67 and a year-to-date (YTD) return of 0.53.

- As of September 18, 2026, the stock price of ₹2748.6 is above the daily 20-day SMA (₹2653.2) and 50-day SMA (₹2602.43).
- The daily Supertrend indicator is bullish at ₹2508.16, and the weekly Supertrend indicator is bullish at ₹2210.5.
- The company has achieved a 6-month return of 0.67 and a year-to-date return of 0.53.
- The monthly trend shows a bullish Supertrend at ₹1610.02 with a positive plus DI of 25.28.

### Bear Case

The company's stock has experienced significant volatility, as indicated by an annualized volatility of 39% and a maximum drawdown of -42%. While the current drawdown is -3%, this follows a substantial historical decline. The Average True Range (ATR) at 3.93% suggests that price swings can be considerable relative to the stock price.

- Annualized volatility stands at 39% as of 2026-09-18.
- The stock has experienced a maximum drawdown of -42%.
- The current drawdown is -3% as of 2026-09-18.
- The Average True Range (ATR) is 3.93%.

### FAQs

**What key corporate actions and upcoming events should investors monitor for Caplin Point Laboratories?**

Caplin Point Laboratories announced a final dividend of ₹4 per share (200% on a face value of ₹2) for the financial year 2025-26, with a record date of September 18, 2026. The company will also hold its 35th Annual General Meeting (AGM) on September 25, 2026, via video conferencing. During the AGM, the adoption of FY2025-26 financials, declaration of the final dividend, and ratification of an interim dividend (totaling ₹8 per share for the year) will be discussed. Additionally, approvals for the re-appointment of Dr. Sridhar Ganesan as Managing Director and Mr. D. Muralidharan as Whole Time Director are on the agenda. The company also submitted its Business Responsibility and Sustainability Report (BRSR) for FY2025-26, highlighting 36.65% renewable energy usage and ₹4.70 Crores spent on CSR.

**How has Caplin Point Laboratories' stock performed recently, and what are the key technical indicators?**

As of September 18, 2026, Caplin Point Laboratories' stock has shown varied returns across different periods. It has returned 6% in the last trading day, 9% in the last month, and 18% in the last year. Notably, it has achieved a 67% return in the last six months and a 53% year-to-date return. Technical indicators show a bullish trend on daily, weekly, and monthly timeframes, with the Supertrend indicator at 2508.16 on a daily basis. Key support levels are observed around ₹2675.0, ₹2652.4, and ₹2624.5, while a resistance level is noted at ₹2877.3.

**What is the company's risk and volatility profile based on recent data?**

Caplin Point Laboratories has an annualized volatility of 0.39 and an Average True Range (ATR) of 3.93% as of September 18, 2026. The current drawdown is -3%, with a maximum drawdown recorded at -42%. The downside deviation stands at 0.26.

- SERIES:EQ |PURPOSE:DIVIDEND - RS 4 PER SHARE |FACE VALUE:2 |RECORD DATE:18-Sep-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-
- Caplin Point Laboratories Limited has informed the Exchange regarding 'Letter to Shareholders'. |SUBJECT: Updates
- Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Caplin Point Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026 |SUBJECT: Shareholders meeting
- Caplin Point Laboratories Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Reporting (BRSR)'. |SUBJECT: Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹2,601.9
- Risk regime: Price Risk Requires Attention

### Support levels
- 2498.7
- 2022.5
- 1954.9

### Resistance levels
- 2877.3

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +5.85% |
| return_10 | -3.39% |
| return_1m | +8.65% |
| return_1y | +18.40% |
| return_20 | +8.65% |
| return_3m | +16.50% |
| return_5 | -1.67% |
| return_6m | +66.76% |
| return_since_start | +9.41% |
| return_ytd | +52.79% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -41.75% |
| annualized_volatility | +38.95% |

## Quarterly financials

Quarterly financials are not currently available.

## Official filings

- 2026-09-04 — Corporate Action Notice: Caplin Point Laboratories Limited - Ex-Date: 18-Sep-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-09-04 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_04092026150707_Letter_to_Shareholder_sd.pdf)
- 2026-09-04 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_04092026152041_AGM_Newspaper_Ad_Intimation_LH_sd.pdf)
- 2026-09-03 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_03092026124351_SE_Intimation__NOTICE_signed.pdf)
- 2026-09-03 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_03092026124934_BRSR_2025-26_SE_intimation_signed.pdf)
- 2026-09-03 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_10106_WebXMLFile_20260903_172151981.xml)
- 2026-09-03 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_10106_WebXMLFile_20260903_172143068.xml)
- 2026-09-02 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_02092026172729_Spurt_in_Volume_sd.pdf)
- 2026-09-02 — Annual Report: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/annual_reports/AR_31201_CAPLIPOINT_2025_2026_A_18753031_03092026123603.pdf)
- 2026-09-01 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/content/RSS/Online_announcements.xml)
- 2026-09-01 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_01092026175916_INVIMA_Facility_Approval_SD.pdf)
- 2026-08-21 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_21082026191221_Stock_Exchange_intimation_of_USFDA_Audit_signed.pdf)
- 2026-08-19 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_19082026180100_SE_Transcript_final.pdf)
- 2026-08-12 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_12082026134040_Outcome.pdf)
- 2026-08-12 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_12082026183932_Earningcall_outcome_12082026.pdf)
- 2026-08-12 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_12082026145814_Change_in_Director.pdf)
- 2026-08-12 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_10106_WebXMLFile_20260812_150159883.xml)
- 2026-08-12 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/OUTCOME_10106_WebXMLFile_20260812_150926265.xml)
- 2026-08-12 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_12082026133557_Record_date_intimations.pdf)
- 2026-08-12 — Generic Announcement: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_12082026132945_Outcome.pdf)
- 2026-08-12 — Earnings Presentation: Caplin Point Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_12082026150548_Outcome.pdf)
- 2026-07-30 — Official Filing: Caplin Point Laboratories Limited will hold an Earning/Quarterly Call on August 12, 2026, at 16:30:00 IST to discuss the financial performance for the quarter ended June 30, 2026. The virtual group meeting is open to all investors/general public, with dial-in details and a registration link provided. G Venkatram is the contact person for this event.
- 2026-07-30 — Generic Announcement: Caplin Point Laboratories Limited will hold a post-results conference call on August 12, 2026, at 4:30 PM IST to discuss financial performance for the quarter ended June 30, 2026. The call will include management representatives and is subject to change. — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_30072026143519_Analysts_Call__Q1_Intimation.pdf)
- 2026-07-11 — Generic Announcement: Caplin Point Laboratories Limited submitted a certificate for the quarter ended June 30, 2026, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The company's Registrar and Transfer Agent, Integrated Registry Management Services Private Limited, confirmed that securities received for dematerialization were processed within 15 days, with certificates mutilated and cancelled, and depositories substituted in the register of members. — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_11072026141625_SEintimation_74_5_.pdf)
- 2026-06-27 — Generic Announcement: Caplin Point Laboratories Limited will close its trading window for dealing in the company's securities from July 01, 2026, due to the finalization of unaudited financial results for the quarter ending June 30, 2026. The window will reopen 48 hours after the results are declared to the stock exchanges. — [Official attachment](https://nsearchives.nseindia.com/corporate/CAPLINPOINT_27062026150933_TWC_intimation_270626_signed.pdf)

## News and market events

- 2026-09-09 — MONEYCONTROL: **Trade Spotlight: How should you trade Marico, Narayana Hrudayalaya, Granules, Laurus Labs, Caplin Point, Tata Technologies, and others on September 9?** — Trade Spotlight — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-marico-narayana-hrudayalaya-granules-laurus-labs-caplin-point-tata-technologies-and-others-on-september-9-14025670.html)
- 2026-09-04 — Mint: **Stock market today: Gift Nifty hints a positive start; eight day trading stocks to buy on Friday, 4 September** — Indian stock market indices, Sensex and Nifty 50, are expected to open higher on 4 September, following positive global cues. Previous sessions saw declines, but easing bond yields may boost risk assets. Cautious trading is projected ahead of key US nonfarm payrolls data. — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-gift-nifty-hints-a-positive-start-eight-day-trading-stocks-to-buy-on-friday-4-september-11788485416492.html)
- 2026-09-02 — BUSINESSTODAY: **Mphasis, Engineers India, Caplin Point: Top stocks to trade — Key levels, target prices & stop loss** — Stocks to buy, Stock picks, Stocks to trade, trading views, Mphasis, Caplin Point Laboratories, Engineers India, Mphasis shares, Caplin Point shares, Engineers India shares, Mphasis share price, Caplin Point share price, Engineers India share price, Mphasis stock price, Caplin Point stock price, Engineers India stock price, Mphasis target price, Caplin Point target price, Engineers India target price — [Source](https://www.businesstoday.in/markets/stocks/story/mphasis-engineers-india-caplin-point-top-stocks-to-trade-key-levels-target-prices-stop-loss-552713-2026-09-02)
- 2026-09-02 — CNBC-TV18: **These are the three Pharma stocks that should be on your radar today** — All the three Pharma stocks in focus today, Gland Pharma, Caplin Point and Nephrocare Health, have risen between 50% to 70% so far this year. — [Source](https://www.cnbctv18.com/market/pharma-stocks-today-caplin-point-gland-pharma-nephrocare-health-services-share-price-usfda-gmp-acquisition-impact-19981919.htm)
- 2026-08-24 — MONEYCONTROL: **Heranba Industries gains 3% as Q1 profit rises; Aurobindo Pharma, Caplin Point Labs fall on USFDA observations** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/heranba-industries-gains-3-as-q1-profit-rises-aurobindo-pharma-caplin-point-labs-fall-on-usfda-observations-14013467.html)
- 2026-08-24 — BUSINESS: **Stock Alert: Caplin Point Lab, Natco pharma, Federal Bank, B. R. Goyal Infra** — Shares of Steel Authority of India (SAIL) barred from fresh F&O positions on 24 August 2026. — [Source](https://www.business-standard.com/markets/capital-market-news/stock-alert-caplin-point-lab-natco-pharma-federal-bank-b-r-goyal-infra-126082400105_1.html)
- 2026-08-24 — Economic Times: **Stocks in news: Reliance Industries, Bank of Baroda, Power Grid, NATCO Pharma and JSW Infra** — Indian equity markets closed largely unchanged on Friday, August 21, after a volatile trading session. Several companies, including Reliance Industries and Bank of Baroda, reported significant corporate developments. Power Grid Corporation and Jubilant Pharmova also announced key project wins and regulatory approvals. NATCO Pharma and Caplin Point Laboratories received observations from the US FDA after inspections. Mobile manufacturing stocks are expected to gain attention following a new gover... — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-reliance-industries-bank-of-baroda-power-grid-natco-pharma-and-jsw-infra/articleshow/133444199.cms)
- 2026-08-23 — CNBC-TV18: **Stocks to Watch for August 24: Reliance Industries, NATCO Pharma, Bank of Baroda** — RIL shareholders approved resolutions on Aug 20, 2026. Caplin Point, NATCO Pharma, and Choksi Labs received US FDA Form 483 observations. Mobile & EMS stocks in focus after new manufacturing scheme. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-24-reliance-industries-natco-pharma-bank-of-baroda-federal-bank-jubilant-pharmova-apollo-micro-systems-19974715.htm)
- 2026-08-22 — BUSINESS: **Caplin Point Laboratories' arm receives Form 483 with 10 observations from USFDA** — Caplin Point Laboratories announced that the US Food and Drug Administration (USFDA) conducted an unannounced inspection of its subsidiary Caplin Steriles' injectable and ophthalmic manufacturing facility in Gummidipoondi, Tamil Nadu. — [Source](https://www.business-standard.com/markets/capital-market-news/caplin-point-laboratories-arm-receives-form-483-with-10-observations-from-usfda-126082200115_1.html)
- 2026-08-21 — CNBC-TV18: **Caplin Point arm gets 10 USFDA observations after unannounced inspection; no data integrity issues** — The USFDA issued 10 observations after inspecting Caplin Steriles’ Gummidipoondi facility. The company said they are procedural in nature, with none related to data integrity or repeated from earlier inspections. — [Source](https://www.cnbctv18.com/business/companies/caplin-point-arm-gets-10-usfda-observations-after-unannounced-inspection-no-data-integrity-issues-19974709.htm)
- 2026-07-15 — The Hindu: **Gift Nifty points to flat opening; earnings, global cues to drive markets today** — Investor focus has shifted to the earnings season, with global cues and easing oil prices expected to drive market sentiment — [Source](https://www.thehindubusinessline.com/markets/gift-nifty-points-to-flat-opening-earnings-global-cues-to-drive-markets-today/article71223872.ece)
- 2026-07-15 — The Hindu: **Sensex today | Stock Market Live: Stock to buy today: Caplin Point Laboratories** — Sensex, Nifty, Share Prices LIVE: The short-term outlook is bullish for Caplin Point Laboratories. The stock has been consolidating within its broader uptrend for more than two weeks between ₹2,500 and ₹2,700. We expect the stock to make a bullish breakout above ₹2,700 and resume the broader uptrend. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-15-july-2026/article71220956.ece)
- 2026-07-15 — The Hindu: **Stock to buy today: Caplin Point Laboratories (₹2,658) – BUY** — Traders can buy Caplin Point Laboratories shares now at ₹2,658. Accumulate on dips at ₹2,580. Keep the stop-loss at ₹2,480. Trail the stop-loss up to ₹2,695 as soon as the stock goes up to ₹2,730. — [Source](https://www.thehindubusinessline.com/portfolio/technical-analysis/stock-to-buy-today-caplin-point-laboratories-2658-buy/article71221000.ece)

## Business profile

**Strategic vision:** Pharmaceutical company engaged in R&D, manufacturing, and marketing.

### Business segments
- **Finished Formulations:** Production of a wide range of pharmaceutical formulations, covering over 36 therapeutic sections with more than 650 products.
- **Active Pharmaceutical Ingredients (APIs):** Manufacturing of Active Pharmaceutical Ingredients (APIs) as part of its pharmaceutical product offerings.
- **Clinical Research:** Engagement in clinical research activities related to pharmaceutical product development.

### Competitive strengths
- Global product registrations across diverse geographies
- USFDA/EU-GMP approved injectable facility
- Extensive product portfolio covering numerous therapeutic sections

## Related stocks

- [360ONE (Financial Services)](https://faxioms.com/stocks/360one) — +1.96%
- [3MINDIA (Diversified)](https://faxioms.com/stocks/3mindia) — +5.50%
- [AADHARHFC](https://faxioms.com/stocks/aadharhfc) — -1.42%
- [AARTIIND](https://faxioms.com/stocks/aartiind) — +3.19%
- [AAVAS](https://faxioms.com/stocks/aavas) — -1.07%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/caplipoint
Markdown representation: https://faxioms.com/stocks/caplipoint?render=md